Connect with us

Health

New York Doctor Indicted in Louisiana for Sending Abortion Pills There

Published

on

New York Doctor Indicted in Louisiana for Sending Abortion Pills There

A state grand jury in Louisiana has indicted a New York doctor for providing abortion pills to a Louisiana resident. The case appears to be the first time criminal charges have been filed against an abortion provider for sending pills into a state with an abortion ban.

The charges mark a new chapter in an escalating showdown between states that ban abortion and those that want to protect and expand access to it. It is challenging one of the foremost strategies used by states that support abortion rights: shield laws intended to provide legal protection to doctors who prescribe and send abortion pills to states with bans.

The charges were brought against Dr. Margaret Carpenter, who was operating under New York’s telemedicine abortion shield law, which stipulates that New York authorities will not cooperate with prosecutions or other legal actions filed against New York abortion providers by other states.

Telemedicine abortion shield laws, which have been adopted by eight states so far, have become a significant avenue for providing access to abortion for women in states with bans without requiring them to leave their state. Doctors, nurse practitioners and other health care providers in states with shield laws have been sending more than 10,000 abortion pills per month to states with abortion bans or restrictions.

Legal experts said the case ratchets up the legal wars over abortion and will almost certainly end up in federal court and possibly the Supreme Court. It is expected to become a major test of whether states can apply criminal laws to people acting outside their borders.

Advertisement

Since the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization overturning the national right to abortion, the United States has been divided between states that restrict abortion and states that protect abortion.

“There’s just been a sense that if you were in a blue state, you’re shielded from the consequences of Dobbs,” said Mary Ziegler, a law professor and abortion expert at the University of California, Davis. “Prosecutions like this undermine that assumption, and we don’t know exactly how, or how much, but you can’t take that for granted.”

Federal courts will have to sort out “where the line will be drawn and even which precedents the courts will be willing to overrule,” she said. “It’s not clear what will happen.”

The Louisiana indictment, by a grand jury in West Baton Rouge Parish, follows what is believed to be the first civil suit filed against an abortion provider in a shield-law state. That case was filed in December by the Texas attorney general, Ken Paxton, also against Dr. Carpenter, for prescribing and sending pills to a woman in Texas.

On Friday, Tony Clayton, the district attorney who oversees West Baton Rouge, said in an interview, “I just don’t know under what theory could a doctor be thinking that you should ship your pills to Louisiana to abort our citizens’ babies.”

Advertisement

He added: “The pill may be legal in New York. It’s not legal in Louisiana.”

In response to the charges, Gov. Kathy Hochul of New York said in a video posted on X, “I will never, under any circumstances, turn this doctor over to the state of Louisiana under any extradition request.” She pledged “to do everything I can to protect this doctor and allow her to continue the work that she’s doing that is so essential.”

The use of abortion medication has grown significantly in recent years. Medication abortions now account for nearly two-thirds of pregnancy terminations in the United States. The method is typically used through 12 weeks of pregnancy and involves two drugs — mifepristone, which stops a pregnancy from developing, followed a day or two later by misoprostol, which causes contractions similar to a miscarriage.

In 2021, the Food and Drug Administration lifted a rule requiring patients to obtain mifepristone in person, allowing the medication to be sent through the mail.

The ability to mail the medications, bolstered by shield laws, has made it much more difficult for states with bans to prevent their residents from getting access to abortion. The actions filed against Dr. Carpenter in Texas and Louisiana are part of a campaign to limit that access.

Advertisement

Abortion opponents are also pressing the Trump administration to revive a 151-year-old federal anti-vice law known as the Comstock Act and use it to try to prevent the mailing of abortion pills.

In the Louisiana case, the grand jury indicted Dr. Carpenter and her medical practice for “criminal abortion by means of abortion-inducing drugs.”

Dr. Carpenter, of New Paltz, N.Y., did not comment on the case on Friday, and efforts to reach lawyers representing her were unsuccessful.

The court documents, which include few details, indicate that the case involved a girl who was under 18 whose mother ordered abortion pills and gave them to her in April 2024. The mother was also charged with violating the state’s abortion ban.

Mr. Clayton, the West Baton Rouge district attorney, said the authorities became aware of the case after a police officer responded to a 911 call placed by the teenager.

Advertisement

“The officer at the time thought he was dealing with a child who was having a miscarriage,” Mr. Clayton said. After the police took the teenager to a hospital, the authorities learned that she had taken abortion medication and the investigation became criminal, he said.

Mr. Clayton, who declined to disclose the age or other details about the girl, said that “the evidence will show that the child had planned a reveal party” and did not want an abortion. He said that charges would not be filed against the girl.

Police records show that the mother, whose name The New York Times is not disclosing to protect the identity of her daughter, was arrested and released on bond. Attempts to reach her on Friday were unsuccessful.

“The allegations in this case have nothing to do with reproductive health care,” said Liz Murrill, the state attorney general. “This is about coercion. This is about forcing somebody to have an abortion who didn’t want one.”

The attorney general of New York, Letitia James, said in a statement, “This cowardly attempt out of Louisiana to weaponize the law against out-of-state providers is unjust and un-American.”

Advertisement

She added: “Medication abortion is safe, effective and necessary, and New York will ensure that it remains available to all Americans who need it.”

Dr. Carpenter is a specialist in reproductive health and a co-founder of the Abortion Coalition for Telemedicine, an organization that advocates access to telehealth abortion in all 50 states.

“Shield laws across the country enable licensed health care professionals to successfully deliver reproductive health care to patients in under-resourced areas nationwide,” the coalition said in a statement on Friday, adding, “This state-sponsored effort to prosecute a doctor providing safe and effective care should alarm everyone.”

Anti-abortion activists praised the Louisiana charges.

“This case exposes how mail-order abortion drugs are fueling an epidemic of coercion, a new form of domestic violence against mothers and their babies,” Katie Daniel, director of legal affairs for SBA Pro-Life America, said in a statement. The statement commended Louisiana for tightening laws against abortion medication and said, “In blue states, pro-abortion politicians are doing the polar opposite, shielding abortionists.”

Advertisement

In the Texas lawsuit, Dr. Carpenter was accused of providing abortion pills to a 20-year-old woman in July. The suit said the woman later asked the “biological father of her unborn child” to take her to the emergency room because of “severe bleeding,” and he learned at that time that she was nine weeks pregnant.

Mr. Paxton said that by filing the Texas lawsuit, he was seeking to have the court stop Dr. Carpenter from continuing to provide abortion medication to patients in Texas, and to apply Texas’ ban on abortion to her. The ban carries a penalty of at least $100,000 for each violation.

Kirsten Noyes contributed research.

Health

Guava for Weight Loss Is a Real Thing—Here’s the Juicy Truth

Published

on

Guava for Weight Loss Is a Real Thing—Here’s the Juicy Truth


Advertisement





How Guava for Weight Loss Melts Belly Fat Faster




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Single workout cuts cravings, offering new hope for smokers trying to quit

Published

on

Single workout cuts cravings, offering new hope for smokers trying to quit

NEWYou can now listen to Fox News articles!

If you’re trying to quit smoking, try a brisk walk or bike ride to curb your craving for a cigarette.

Researchers found that just one workout can reduce the urge to light up. But the type of exercise you do and how you do it makes a big difference.

High-intensity, aerobic exercise is most effective at reducing people’s cigarette cravings, a review of 59 randomized controlled trials involving more than 9,000 adults found.

FITNESS EXPERT REVEALS SIMPLE RULE TO GET IN SHAPE WITHOUT DREADING THE GYM: ‘JUST MOVE’

Advertisement

“Single-bout exercise reduced acute cravings immediately and up to 30 minutes post-exercise, but not longer-term cravings,” the authors of the study, published in the Journal of Sport and Health Science, reported.

Aerobic exercise is the most effective form of exercise for reducing cravings for cigarettes, researchers found. (iStock)

The research team highlighted other key findings from their study of “exercise-based interventions for smoking cessation.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Exercise training made people between 15% and 21% more likely to abstain from smoking than those who didn’t exercise, the authors found.

Advertisement

Researchers found that exercise curbs people’s cigarette cravings for up to 30 minutes after they stop exercising. (iStock)

Regular exercise also caused smokers to cut back by an average of two cigarettes per day.

In addition to being a free and accessible method for reducing smoking, exercise is also effective at reducing anxiety and stress, which drive many people to smoke.  

CLICK HERE FOR MORE LIFESTYLE STORIES

Advertisement

The authors suggest that because exercise boosts feel-good hormones, such as dopamine, and reduces the stress hormone cortisol, smokers who work out feel less inclined to use nicotine as a brain reward.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Exercise should be integrated into other smoking cessation programs to enhance quit success, the authors concluded.

Exercise releases similar feel-good brain chemicals that people get from cigarettes, researchers suggested. (iStock)

They also noted that none of the trials addressed vaping and recommended that future research target the use of electronic cigarettes.

Advertisement

Continue Reading

Health

Hantavirus Vaccines and Treatments Are in the Pipeline

Published

on

Hantavirus Vaccines and Treatments Are in the Pipeline

The deadly hantavirus outbreak aboard the cruise ship MV Hondius has put the spotlight on a rare pathogen that typically attracts relatively little attention, even from scientists.

There are no targeted treatments for hantaviruses, which are typically carried by rodents, and no widely available vaccines. So when passengers began falling ill in the middle of the Atlantic Ocean, doctors and public health experts were limited in what they could offer.

“It’s kind of a wake-up call,” said Dr. Vaithi Arumugaswami, an infectious disease researcher at the University of California, Los Angeles. “Our tool kit is almost empty.”

That’s not for lack of trying. A handful of scientific teams around the world have been working — for decades, in some cases — to develop hantavirus treatments and vaccines. But it has not been easy to find funding or nurture commercial interest in medical interventions for a type of pathogen that does not infect humans often and does not spread easily between people.

“It’s not an airborne, highly contagious viral threat, so it hasn’t been as high a priority for groups trying to prevent pandemics,” said Jay Hooper, a virologist at the United States Army Medical Research Institute of Infectious Diseases.

Advertisement

But there are promising vaccines and treatments in development. And some of them, experts said, could be moved through the pipeline rapidly if hantavirus interventions became a priority.

“I do think there are things that are sitting there on the bench that could be quickly developed,” said Dr. Ronald Nahass, the president of the Infectious Diseases Society of America. “But nothing is ready.”

There are two main types of hantaviruses: Old World viruses, which circulate primarily in Asia and Europe, and New World viruses, which are found in the Americas. The cruise ship outbreak has been linked to a New World virus known as the Andes virus, which is endemic to South America and is the only hantavirus known to spread between people.

There are vaccines that target some of the Old World viruses in Asia, but their efficacy is modest, experts said. And there are no licensed vaccines for the New World viruses, which include the Sin Nombre virus endemic to rodents in the western United States.

But there are some in development. Dr. Hooper and his colleagues have developed a DNA vaccine for the Andes virus, which proved promising in a small phase 1 trial. Under certain dosing regimens, the researchers found, more than 80 percent of participants produced neutralizing antibodies. “It’s pretty amazing,” said Dr. Hooper, who is an inventor on multiple hantavirus vaccine patents owned by the U.S. government. “Getting these kinds of neutralizing antibodies in humans is impressive.”

Advertisement

There were drawbacks, including that the vaccine seemed to require at least three doses. But the vaccine is ready for further development “if there’s a need,” Dr. Hooper said. “We’ve done the science. It’s just other forces that are required to move vaccines forward — markets, government demand.”

Other teams have potential vaccines in earlier stages of development. For instance, Bryce Warner, a hantavirus researcher at the University of Saskatchewan, and his colleagues are exploring a variety of approaches, including a nasal vaccine that they hope might spark a more robust immune response in the airway.

But the research, which is being conducted in hamsters, is still in early stages, and hantavirus vaccine candidates can be challenging to move forward. Scientists lack good large-animal models for hantaviruses, Dr. Warner said, and human cases are rare enough to make trials tricky. “It’s very difficult to conduct a clinical trial when you only have a limited number of cases annually,” he said. “You don’t have the numbers of people to really show a robust effect.”

Currently, the primary treatment for hantavirus infection is supportive care, which may include supplemental oxygen or heart-lung bypass machines. Doctors also sometimes prescribe an existing antiviral drug, called ribavirin, but there is not strong evidence that it is effective for New World viruses, scientists said.

The hunt for new drugs is underway, though. At U.C.L.A., Dr. Arumugaswami and his colleagues found that favipiravir, an antiviral approved to treat influenza in Japan, inhibited the Andes virus in human cells. They also identified several compounds that had broad antiviral activity, blocking hantaviruses as well as other types of viruses, in human organoids, miniature clusters of tissue that mimic the function of organs.

Advertisement

Other teams have been working to develop therapeutic antibody treatments, often working from blood samples collected from hantavirus survivors. “We were able to isolate the natural antibodies that people are making and basically winnow them down and find one that was really good,” said Kartik Chandran, a virologist at the Albert Einstein College of Medicine in New York. “We actually found several.”

When Dr. Chandran and his colleagues tested these antibodies in hamsters, one produced especially encouraging results: It seemed to work against both Old and New World hantaviruses and was effective even when given relatively late in the course of infection, Dr. Chandran said.

(Dr. Chandran is listed as an inventor on patents for hantavirus antibodies.)

Several other teams have also produced antibodies that were broadly effective in small animals, but that is where a number of potential products have stalled, experts said.

“We have a lead drug, and now what we need is someone to pay the money, which would be something like $40 million, to go the next step,” said Dr. James Crowe, director of the Vanderbilt Center for Antibody Therapeutics. “We have neither government nor foundation nor company support to do that. So we’re just waiting to find a partner.”

Advertisement

(Vanderbilt University has applied for patents related to these antibodies; Dr. Crowe is listed as the inventor.)

Experts said that they hoped the current outbreak might help bring attention to a family of often-overlooked viruses.

“Certainly judging by just my inbox and text messages, there’s a renewed interest in these agents, and renewed interest in maybe at least revisiting where they are in the priority list,” Dr. Chandran said.

Whether that interest can be sustained after the virus fades from the headlines remains to be seen, experts acknowledged.

“Raising awareness never hurts,” Dr. Warner said. “We’ll see whether or not it leads to anything tangible, at least in terms of funding and resources for advancing some of these things that are lacking for hantavirus.”

Advertisement
Continue Reading
Advertisement

Trending